Skip to main content

Table 2 Results from Phase II clinical study in Non-Small Cell Lung Cancer (NSCLC) with a median follow-up time of 44-months [16]

From: Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010"

Phase II NSCLC (NCT 00290355)

Results recMAGE-A3 + AS02B

Primary endpoint

DFI

HR: 0.75 (95% CI: 0.46-1.23)

recMAGE-A3 + AS02B vs . Placebo

p = 0.127 in favor of MAGE-A3 ASCI

Secondary endpoints

Safety

Well tolerated

 

Humoral immune response

Response induced in > 98% patients

 

Cellular immune response

Response induced in 41% patients

  1. DFI: disease Free Interval
  2. HR: Hazard Ratio
  3. CI: Confidence Interval
  4. NSCLC: Non-Small Cell Lung Cancer